Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P02489
UPID:
CRYAA_HUMAN
Alternative names:
Heat shock protein beta-4
Alternative UPACC:
P02489; A0A140G945; E9PHE4; Q53X53
Background:
Alpha-crystallin A chain, also known as Heat shock protein beta-4, plays a crucial role in maintaining the transparency and refractive index of the lens, according to research findings (PubMed:18302245). Its oxidized form functions as a chaperone, preventing protein aggregation under stress (PubMed:22120592, PubMed:31792453, PubMed:18199971, PubMed:19595763). It is essential for lens intermediate filaments formation, working alongside BFSP1, BFSP2, and CRYAA (PubMed:28935373).
Therapeutic significance:
Given its pivotal role in lens transparency and protein aggregation prevention, Alpha-crystallin A chain's dysfunction is linked to Cataract 9, multiple types, a condition leading to visual impairment or blindness. Understanding the role of Alpha-crystallin A chain could open doors to potential therapeutic strategies for cataract and related ocular diseases.